Drugs / FT516
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04630769 | Apr 2021 → Jan 2022 | fallopian tube adenocarcinoma, ovarian cancer, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04551885 | Sep 2020 → Aug 2023 | cancer | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04363346 | May 2020 → Feb 2021 | COVID-19 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04023071 | Oct 2019 → Oct 2023 | B-cell neoplasm, acute myeloid leukemia | Fate Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551885 ↗ |
| Modality | Cell therapy | “FT516 is an induced pluripotent stem cell (iPSC)-derived natural killer-cell therapy” PMID 40610174 ↗ Jul 2025 |
| Route | Intravenous | “FT516 was administered intravenously at escalating doses” PMID 40610174 ↗ Jul 2025 |